vs
Side-by-side financial comparison of Lucid Diagnostics Inc. (LUCD) and Nuvve Holding Corp. (NVVE). Click either name above to swap in a different company.
Nuvve Holding Corp. is the larger business by last-quarter revenue ($1.9M vs $1.2M, roughly 1.6× Lucid Diagnostics Inc.). Nuvve Holding Corp. runs the higher net margin — -314.5% vs -858.5%, a 544.1% gap on every dollar of revenue. On growth, Nuvve Holding Corp. posted the faster year-over-year revenue change (7.9% vs 3.3%). Over the past eight quarters, Nuvve Holding Corp.'s revenue compounded faster (8.3% CAGR vs 7.9%).
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics firm focused on non-invasive screening tests for upper gastrointestinal diseases, including early detection of esophageal cancer and pre-cancerous lesions. It mainly serves healthcare providers and clinical partners across the United States, targeting at-risk patient populations.
Nuvve Holding Corp. is a global technology provider specializing in vehicle-to-grid (V2G) solutions for electric vehicles. It delivers intelligent energy management platforms that allow EV batteries to feed excess stored power back to electrical grids, serving commercial fleet operators, utility firms, and residential EV owners across North America, Europe, and Asia-Pacific.
LUCD vs NVVE — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2M | $1.9M |
| Net Profit | $-10.4M | $-6.1M |
| Gross Margin | — | — |
| Operating Margin | -971.0% | -346.7% |
| Net Margin | -858.5% | -314.5% |
| Revenue YoY | 3.3% | 7.9% |
| Net Profit YoY | 16.0% | -19.0% |
| EPS (diluted) | $-0.10 | $-69.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $1.9M | ||
| Q3 25 | $1.2M | $1.6M | ||
| Q2 25 | $1.2M | — | ||
| Q1 25 | $828.0K | $934.3K | ||
| Q4 24 | $1.2M | $1.8M | ||
| Q3 24 | $1.2M | $1.9M | ||
| Q2 24 | $976.0K | $802.2K | ||
| Q1 24 | $1.0M | $779.8K |
| Q4 25 | — | $-6.1M | ||
| Q3 25 | $-10.4M | $-4.5M | ||
| Q2 25 | $-4.4M | — | ||
| Q1 25 | $-26.9M | $-6.9M | ||
| Q4 24 | $-11.5M | $-5.1M | ||
| Q3 24 | $-12.4M | $-1.6M | ||
| Q2 24 | $-11.0M | $-3.9M | ||
| Q1 24 | $-10.6M | $-6.7M |
| Q4 25 | — | -346.7% | ||
| Q3 25 | -971.0% | -319.7% | ||
| Q2 25 | -978.8% | — | ||
| Q1 25 | -1508.1% | -597.9% | ||
| Q4 24 | -1033.8% | -314.2% | ||
| Q3 24 | -997.8% | -95.8% | ||
| Q2 24 | -1146.7% | -718.5% | ||
| Q1 24 | -1078.1% | -929.4% |
| Q4 25 | — | -314.5% | ||
| Q3 25 | -858.5% | -281.9% | ||
| Q2 25 | -381.7% | — | ||
| Q1 25 | -3249.8% | -735.6% | ||
| Q4 24 | -964.2% | -285.2% | ||
| Q3 24 | -1055.5% | -86.0% | ||
| Q2 24 | -1127.6% | -491.0% | ||
| Q1 24 | -1060.1% | -861.1% |
| Q4 25 | — | $-69.41 | ||
| Q3 25 | $-0.10 | $-0.24 | ||
| Q2 25 | $-0.08 | — | ||
| Q1 25 | $-0.52 | $-3.88 | ||
| Q4 24 | $-0.17 | $-1050.64 | ||
| Q3 24 | $-0.25 | $-2.47 | ||
| Q2 24 | $-0.23 | $-6.70 | ||
| Q1 24 | $-0.40 | $-16.89 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $47.3M | $5.5M |
| Total DebtLower is stronger | — | $1.7M |
| Stockholders' EquityBook value | $25.8M | $-1.7M |
| Total Assets | $53.2M | $17.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $5.5M | ||
| Q3 25 | $47.3M | $939.4K | ||
| Q2 25 | $31.1M | — | ||
| Q1 25 | $25.2M | $1.2M | ||
| Q4 24 | $22.4M | $371.5K | ||
| Q3 24 | $14.5M | $325.2K | ||
| Q2 24 | $24.9M | $1.4M | ||
| Q1 24 | $24.8M | $5.3M |
| Q4 25 | — | $1.7M | ||
| Q3 25 | — | $3.0M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $4.8M | ||
| Q4 24 | — | $5.5M | ||
| Q3 24 | — | $2.4M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $-1.7M | ||
| Q3 25 | $25.8M | $-1.4M | ||
| Q2 25 | $7.9M | — | ||
| Q1 25 | $-5.4M | $-3.2M | ||
| Q4 24 | $5.4M | $-1.3M | ||
| Q3 24 | $6.3M | $3.0M | ||
| Q2 24 | $16.0M | $3.3M | ||
| Q1 24 | $11.9M | $6.6M |
| Q4 25 | — | $17.4M | ||
| Q3 25 | $53.2M | $16.8M | ||
| Q2 25 | $38.7M | — | ||
| Q1 25 | $32.8M | $16.5M | ||
| Q4 24 | $30.7M | $16.8M | ||
| Q3 24 | $22.6M | $18.3M | ||
| Q2 24 | $34.1M | $18.5M | ||
| Q1 24 | $32.0M | $23.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.81× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-10.9M | $-4.3M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-4.3M | ||
| Q3 25 | $-10.9M | $-5.1M | ||
| Q2 25 | $-10.5M | — | ||
| Q1 25 | $-12.5M | $-1.8M | ||
| Q4 24 | $-9.9M | $-3.5M | ||
| Q3 24 | $-10.2M | $-3.5M | ||
| Q2 24 | $-11.5M | $-4.0M | ||
| Q1 24 | $-12.6M | $-4.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | $-5.1M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-1.8M | ||
| Q4 24 | — | $-3.5M | ||
| Q3 24 | — | $-3.5M | ||
| Q2 24 | — | $-4.0M | ||
| Q1 24 | — | $-4.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | -317.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -194.9% | ||
| Q4 24 | — | -196.0% | ||
| Q3 24 | — | -182.9% | ||
| Q2 24 | — | -501.7% | ||
| Q1 24 | — | -611.2% |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.3% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | — | 1.5% | ||
| Q1 24 | — | 5.2% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LUCD
Segment breakdown not available.
NVVE
| Engineering Services | $1.1M | 57% |
| Other | $838.4K | 43% |
